VKTX
VKTX
Viking Therapeutics, Inc.
$31.44
-$0.26 (-0.82%)
Mkt Cap: $3.65B
Home / VKTX / Financial Statements

Viking Therapeutics, Inc. (VKTX) Financial Statements

Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.

Metric TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue
$0.00
$0.00
$0.00
$0.00
$0.00
$0.00
Cost of Revenue
$208,000.00
$431,000.00
$0.00
$0.00
$0.00
$0.00
Gross Profit
-$208,000.00
-$431,000.00
$0.00
$0.00
$0.00
$0.00
R&D Expenses
$453.71M
$344.95M ↑239.4%
$101.64M ↑59.3%
$63.81M ↑17.6%
$54.23M ↑20.6%
$44.98M
SG&A Expenses
$48.28M
$48.39M ↓1.8%
$49.28M ↑33.1%
$37.02M ↑129.6%
$16.12M ↑50.6%
$10.70M
Operating Income
-$502.00M
-$393.34M ↓160.6%
-$150.92M ↓49.7%
-$100.83M ↓43.3%
-$70.36M ↓26.4%
-$55.68M
Interest Expense
$32,000.00
$56,000.00 ↓40.4%
$94,000.00 ↑6.8%
$88,000.00 ↑49.2%
$59,000.00 ↑227.8%
$18,000.00
Income Tax
$0.00
$0.00
$0.00
$0.00
$0.00
$0.00
Net Income
-$472.33M
-$359.64M ↓227.1%
-$109.96M ↓28.0%
-$85.89M ↓24.7%
-$68.87M ↓25.2%
-$54.99M
EBITDA
-$501.77M
-$393.34M ↓161.2%
-$150.57M ↓49.8%
-$100.53M ↓43.5%
-$70.06M ↓26.5%
-$55.39M
EPS
-4.14
-3.19 ↓215.8%
-1.01 ↓11.0%
-0.91 ↓3.4%
-0.88 ↓25.7%
-0.70
Shares Out (Diluted)
454.03M
112.67M ↑3.3%
109.04M ↑15.6%
94.35M ↑22.8%
76.83M ↓0.5%
77.20M